CClinicalTrials.gg
Status unknownNCT05829213Updated Apr 25, 2023

A Modified Esophagogastric Reconstruction Method After Laparoscopic Proximal Gastrectomy

An interventional study of "arch-bridge-type" esophagogastric reconstruction after proximal gastrectomy in Proximal Gastric Adenocarcinoma, Adenocarcinoma of Esophagogastric Junction and Anastomosis, sponsored by Peking University. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-04-25.

Sponsored by Peking University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Nov 2021, registered Mar 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The double-flap technique (DFT) is an effective digestive tract reconstruction method after proximal gastrectomy (PG) to reduce the incidence of postoperative reflux esophagitis. But its clinical application is restricted due to the technical complexity. Our surgical team devise a modified esophagogastric reconstructive method which we term the "arch-bridge-type" reconstruction based on the principle of DFT. The aim of this single-arm prospective study is to assess the safety and feasibility of the "arch-bridge-type" reconstruction after PG.

Read the detailed description
  1. The lymphadenectomy is performed according to the Japanese Gastric Cancer Treatment Guidelines.
  2. Transection of the esophagus is performed using a linear stapler 2cm away from the proximal end of the tumor.
  3. Creating the seromuscular flap ("arch-bridge"):

(1) The stomach is resected by a linear stapling device. (2) A "匚" shaped seromuscularflap (3.0cm×4.0cm) is created utilizing electrocautery extracorporeally by dissecting submocosal and muscular layer of the anterior wall of the remnant stomach.

(3) The opening of the flap is interrupted sutured by 4-0 absorbable suture, then the "arch-bridge" is created.

4.The remnant stomach is then inserted into the abdominal cavity, and pneumoperitoneum is re-established to perform the intracorporeal anastomosis.

02

Conditions studied

  • Proximal Gastric Adenocarcinoma
  • Adenocarcinoma of Esophagogastric Junction
  • Anastomosis

Browse trials for

03

In context

Adenocarcinoma

2,004 studies on the registry are indexed under Adenocarcinoma; 375 are open to participants now.

This study's planned enrollment of 30 is below the median of 45 across 1,553 interventional studies indexed under Adenocarcinoma.

Browse Adenocarcinoma studies →

Lead sponsor

Peking University is the lead sponsor of 411 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • histologically proven proximal gastric cancer or adenocarcinoma of esophagogastric junction
  • diameter of the tumor less than 4cm
  • ECOG performance status score ≤2
  • no distant metastasis
  • informed consent is signed

Exclusion criteria

Exclusion Criteria:

  • metastatic gastric cancer or metastatic adenocarcinoma of esophagogastric junction
  • remnant gastric cancer
  • patient requires emergency surgery
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    "arch-bridge-type" reconstruction arm

    In this arm, patients will receive proximal gastrectomy and "arch-bridge-type" reconstruction.

    Procedure: "arch-bridge-type" esophagogastric reconstruction after proximal gastrectomy

Interventions

  • Procedure"arch-bridge-type" esophagogastric reconstruction after proximal gastrectomy

    1. The lymphadenectomy is performed according to the Japanese Gastric Cancer Treatment Guidelines 2. Transection of the esophagus is performed using a linear stapler 2cm away from the proximal end of the tumor. 3. Creating the seromuscular flap ("arch-bridge") 4. The remnant stomach is then inserted into the abdominal cavity, and pneumoperitoneum is re-established to perform the intracorporeal anastomosis.

06

What researchers measure

Primary outcomes

  1. Surgical safety

    The incidence of postoperative complications which were graded using the Clavien-Dindo classification system. The postoperative complications include anastomotic leackage, anastomotic stenosis, abdominal bleeding, gastric emptying disorder, pneumonia complications, etc.

    Time frame: From surgery day to 30 days after surgery

  2. Postoperative long-term quality of life (QoL)

    The QoL is evaluated by postgastrectomy symptom assessment scale (PGSAS-45). Postoperative reflux, abdominal pain, postprandial discomfort, dyspepsia, diarrhea, constipation, dumping syndrome, weight change, food intake per meal, frequency of additional meals, digestive ability, daily work ability, and satisfaction with quality of life will be evaluated in PGSAS-45.

    Time frame: 1 year after surgery

Secondary outcomes

  1. Postoperative body weight status

    Body weight loss will be recorded in outpatient.

    Time frame: 1 year after surgery

  2. Postoperative reflux esophagitis

    Reflux esophagitis will be evaluated by gastroscopy. Reflux esophagitis was graded by the Los Angeles classification.

    Time frame: 1 year after surgery

  3. Refinement of surgery

    During the operation, the whole process of the operation will be videotaped by laparoscopy, and after the operation, the change of the technical process of the operation was judged by comparing the operation in the video and the scheduled operation steps before the operation. In case of technical changes, the surgical team will communicate and discuss with the chief surgeon, and decide whether to adjust and optimize the surgical technique based on the postoperative situation of the patient, so as to form new technical details. Objective metrics include the total operative time, the time of esophagogastric anastomosis, the time of creating the" arch-bridge", intraoperative blood loss, the number of retrieved lymph nodes will be collected.

    Time frame: From surgery day to 30 days after surgery

  4. Postoperative hemoglobin

    Laboratory tests will be done to evaluate the level of hemoglobin.

    Time frame: 1 year after surgery

07

Study locations

1 of 1 sites recruiting
  • Ziyu Li
    Beijing, Beijing 100142, China
    • Ziyu Li, MD PHD · Contact · ziyu_li@hsc.pku.edu.cn · 0086-10-88196605
    • Yinkui Wang, MD PHD · Contact · wykchangfeng@pku.edu.cn · 0086-10-88196606
    • Ziyu Li, M.D. · Principal investigator
    • Fei Shan, M.D. · Sub investigator
    • Yinkui Wang, M.D. · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05829213
Lead sponsor
Peking University
Responsible party
Ziyu Li, MD (Dr. Prof., Peking University) — Principal investigator
First posted
Apr 25, 2023
Start date
Nov 1, 2021
Primary completion
Nov 30, 2024 (estimated)
Completion
Nov 30, 2024 (estimated)
Last update
Apr 25, 2023

Study contacts

Yinkui Wang, MD PHD
Contact
wykchangfeng@pku.edu.cn
0086-10-88196606
Ziyu Li, MD PHD
Contact
ziyu_li@hsc.pku.edu.cn
0086-10-88196605
Ziyu Li, MD PHD
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion